ITB HOLDINGS LLC provides the following services to domestic and foreign companies that are manufacturers, exporters, importers, or distributors:

■ Drug Establishment Registration

■ Drug Product Listing

■ Investigational New Drug (IND) Application

■ New Drug Application (NDA)

■ Abbreviated New Drug Application (ANDA): Generics

■ U.S. Agent Service

■ Label Review

■ Label Design

Any establishment engaged in the manufacture, repacking, relabeling, or salvaging of a drug product for commercial distribution is required to register with FDA. There are exemptions.

FDA defines drugs as

• a substance recognized by an official pharmacopoeia or formulary.
• a substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.
• a substance (other than food) intended to affect the structure or any function of the body.
• a substance intended for use as a component of a medicine but not a device or a component, part or accessory of a device.

FDA’s Center for Drug Evaluation and Research (CDER) regulates

■ Over-the-counter and prescription drugs including biological therapeutics and generic drugs

■ Fluoride toothpaste, antiperspirants, dandruff shampoos, sunscreens, hand sanitizers that are considered “drugs“

■ Prescription Drugs: medicines or any drug product that requires a doctor’s authorization for purchase.

■ Generic Drugs: drug products equivalent to brand name products in terms of quality and performance. A generic drug product is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use.

■ Over-the-Counter (OTC) Drugs: drug products are available to consumers without a doctor’s prescription.

All Drug Establishments must renew their registration between October 1 and December 31, 2021.

FDA has concluded that, based on new information, including clinical trial data results, it is no longer reasonable to believe that oral formulations of Hydroxychloroquine Sulfate (HCQ) and Chloroquine Phosphate (CQ), may be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks. Therefore, FDA revoked the EUA for emergency use of HCQ and CQ to treat COVID-19. The oral formulations of HCQ and CQ are no longer authorized by FDA to treat COVID-19.

Although the Emergency Use Authorization (EUA) for Remdesivir is still in effect, it does not constitute approval of this drug for a COVID-19-related use, and does not authorize the sale of unapproved Remdesivir directly to consumers over the internet to treat COVID-19 or for any other use.